ORIC Pharmaceuticals Inc. (ORIC)
8.00
-0.03 (-0.37%)
At close: Mar 03, 2025, 12:48 PM
No 1D chart data available
| Bid | 8 |
| Market Cap | 568.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -128.53M |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -4.37 |
| Forward PE | -5.52 |
| Analyst | Buy |
| Ask | 8.02 |
| Volume | 153,529 |
| Avg. Volume (20D) | 930,201 |
| Open | 8.04 |
| Previous Close | 8.03 |
| Day's Range | 7.74 - 8.10 |
| 52-Week Range | 6.33 - 16.65 |
| Beta | 1.20 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; an...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 115
Stock Exchange NASDAQ
Ticker Symbol ORIC
Website https://www.oricpharma.com
Analyst Forecast
According to 10 analyst ratings, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 150.00% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 days ago
+2.72%
Oric Pharmaceuticals shares are trading higher. JP...
Unlock content with
Pro Subscription
4 months ago
-0.42%
Oric Pharmaceuticals shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a price target of $17.
